Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)
Sponsored by QLT Inc.
About this trial
Last updated 19 years ago
Study ID
BPH 003
Status
Terminated
Type
Interventional
Phase
Phase 2
Placebo
No
Accepting
21+ Years
Male
Not accepting
Healthy Volunteers
Trial Timing
Ended 19 years ago
What is this trial about?
The purpose of this study is to determine if transurethral photodynamic therapy with
lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged
prostate.
Photodynamic therapy (known as "PDT") is a treatment that uses light to make a drug work.
This means the drug is "light-activated". Light-activated drugs do not work until a certain
color of light shines on the drug. When the drug and the light combine, they react together
to destroy tissue.
This study is investigating PDT with lemuteporfin as a possible treatment for an enlarged
prostate. PDT with lemuteporfin may destroy overgrown prostate tissue and help urinary
symptoms go back to normal.
What are the participation requirements?
Inclusion Criteria
- Men 21 years of age and older.
- Subjects with LUTS due to BPH with AUA SI scores of 13 and over and Qmax between 5 and 15 mL/sec.
- Subjects with urethral treatment length of at least 25 mm.
Exclusion Criteria
- Subjects who have had previous minimally invasive or surgical treatment for BPH.
- Subjects who have unsuitable prostate dimensions.